Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)

NeuroImage

Volumn 45, Issue 4, 2009, Pages 1107-1116

  Langbaum, Jessica B S ^a,m   Chen, Kewei ^a,b,c,m   Lee, Wendy ^a,m   Reschke, Cole ^a,m   Bandy, Dan ^a,m   Fleisher, Adam S ^a,l,m   Alexander, Gene E ^d,m   Foster, Norman L ^f   Weiner, Michael W ^g,h   Koeppe, Robert A ⁱ   Jagust, William J ^j   Reiman, Eric M ^a,e,k,m  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d University of Arizona   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f Imaging and Research   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m ARIZONA ALZHEIMER S CONSORTIUM   (United States)

more..

Author keywords

Alzheimer's disease; MCI; MMSE; Positron emission tomography

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINIMENTAL STATE EXAM; MULTICENTER STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL PARAMETRICAL MAPPING; TEMPORAL CORTEX;

AGED; ALZHEIMER DISEASE; CEREBRAL CORTEX; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 62349097513     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2008.12.072     Document Type: Article

References (56)

1. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., and Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159 (2002) 738-745
2. Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Cappa S., Lenz O., Ludecke S., Marcone A., Mielke R., Ortelli P., Padovani A., Pelati O., Pupi A., Scarpini E., Weisenbach S., Herholz K., Salmon E., Holthoff V., Sorbi S., Fazio F., and Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 62 (2005) 1728-1733
3. Arnaiz E., Jelic V., Almkvist O., Wahlund L.O., Winblad B., Valind S., and Nordberg A. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12 (2001) 851-855
4. Bokde A.L., Teipel S.J., Drzezga A., Thissen J., Bartenstein P., Dong W., Leinsinger G., Born C., Schwaiger M., Moeller H.J., and Hampel H. Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 20 (2005) 352-357
5. Chase T.N., Foster N.L., Fedio P., Brooks R., Mansi L., and Di Chiro G. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann. Neurol. 15 Suppl (1984) S170-S174
6. Chételat G., Eustache F., Viader F., de la Sayette V., Pélerin A., Mézenge F., Hannequin D., Dupuy B., Baron J.C., and Desgranges B. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11 (2005) 14-25
7. Chételat G., Desgranges B., Landeau B., Mézenge F., Poline J.B., de la Sayette V., Viader F., Eustache F., and Baron J.C. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131 (2008) 60-71
8. Choo I.H., Lee D.Y., Youn J.C., Jhoo J.H., Kim K.W., Lee D.S., Lee J.S., and Woo J.I. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Dis. Assoc. Disord. 21 (2007) 77-84
9. de Leon M.J., Ferris S.H., George A.E., Reisberg B., Christman D.R., Kricheff I.I., and Wolf A.P. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J. Cereb. Blood Flow Metab. 3 (1983) 391-394
10. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., and Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10966-10971
11. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., Tsui W.H., Kandil E., Boppana M., Daisley K., Wang G.J., Schlyer D., and Fowler J. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22 (2001) 529-539
12. De S.S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., Tsui W.H., Kandil E., Boppana M., Daisley K., Wang G.J., Schlyer D., and Fowler J. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22 (2001) 529-539
13. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., Schwaiger M., and Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 1104-1113
14. Drzezga A., Grimmer T., Riemenschneider M., Lautenschlager N., Siebner H., Alexopoulus P., Minoshima S., Schwaiger M., and Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 46 (2005) 1625-1632
15. Duara R., Grady C.L., Haxby J.V., Sundaram M., Cutler N.R., Heston L., Moore A., Schlageter N., Larson S., and Rapoport S.I. Positron emission tomography in Alzheimer's disease. Neurology 36 (1986) 879-887
16. Foster N.L., Chase T.N., Fedio P., Patronas N.J., Brooks R.A., and Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 33 (1983) 961-965
17. Foster N.L., Chase T.N., Mansi L., Brooks R., Fedio P., Patronas N.J., and Di Chiro G. Cortical abnormalities in Alzheimer's disease. Ann. Neurol. 16 (1984) 649-654
18. Frisoni G.B., Henneman W.J.P., Weiner M.W., Scheltens P., Vellas B., Reynish E., Hudecova J., Hampel H., Burger K., Blennow K., Waldemar G., Johannsen P., Wahlund L.-O., Zito G., Rossini P.M., Winblad B., and Barkhof F. The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. Alzheimer's Dement. 4 (2008) 255-264
19. Greenberg S.M., Grabowski T., Gurol M.E., Skehan M.E., Nandigam R.N., Becker J.A., Garcia-Alloza M., Prada C., Frosch M.P., Rosand J., Viswanathan A., Smith E.E., and Johnson K.A. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann. Neurol. 64 (2008) 587-591
20. Haxby J.V., Grady C.L., Koss E., Horwitz B., Heston L., Schapiro M., Friedland R.P., and Rapoport S.I. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 47 (1990) 753-760
21. Herholz K., Perani D., Salmon E., Franck G., Fazio F., Heiss W.D., and Comar D. Comparability of FDG PET studies in probable Alzheimer's disease. J. Nucl. Med. 34 (1993) 1460-1466
22. Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Schonknecht P., Ito K., Mielke R., Kalbe E., Zundorf G., Delbeuck X., Pelati O., Anchisi D., Fazio F., Kerrouche N., Desgranges B., Eustache F., Beuthien-Baumann B., Menzel C., Schroder J., Kato T., Arahata Y., Henze M., and Heiss W.D. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17 (2002) 302-316
23. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., Crain B., Hulette C., Earl N., and Coleman R.E. FDG PET imaging in patients with pathologically verified dementia. J. Nucl. Med. 41 (2000) 1920-1928
24. Ibanez V., Pietrini P., Alexander G.E., Furey M.L., Teichberg D., Rajapakse J.C., Rapoport S.I., Schapiro M.B., and Horwitz B. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50 (1998) 1585-1593
25. Jagust W.J., Friedland R.P., Budinger T.F., Koss E., and Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 38 (1988) 909-912
26. Jagust W., Reed B., Mungas D., Ellis W., and DeCarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 69 (2007) 871-877
27. Johnson K.A., Gregas M., Becker J.A., Kinnecom C., Salat D.H., Moran E.K., Smith E.E., Rosand J., Rentz D.M., Klunk W.E., Mathis C.A., Price J.C., DeKosky S.T., Fischman A.J., and Greenberg S.M. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 62 (2007) 229-234
28. Kawano M., Ichimiya A., Ogomori K., Kuwabara Y., Sasaki M., Yoshida T., and Tashiro N. Relationship between both IQ and Mini-Mental State Examination and the regional cerebral glucose metabolism in clinically diagnosed Alzheimer's disease: a PET study. Dement. Geriatr. Cogn. Disord. 12 (2001) 171-176
29. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
30. McGeer E.G., Peppard R.P., McGeer P.L., Tuokko H., Crockett D., Parks R., Akiyama H., Calne D.B., Beattie B.L., and Harrop R. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can. J. Neurol. Sci. 17 (1990) 1-11
31. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
32. Mielke R., Herholz K., Grond M., Kessler J., and Heiss W.D. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol. Aging 13 (1992) 93-98
33. Mielke R., Schroder R., Fink G.R., Kessler J., Herholz K., and Heiss W.D. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 91 (1996) 174-179
34. Minoshima S., Foster N.L., and Kuhl D.E. Posterior cingulate cortex in Alzheimer's disease. Lancet 344 (1994) 895
35. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., and Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36 (1995) 1238-1248
36. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., and Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann.Neurol. 42 (1997) 85-94
37. Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., and Kuhl D.E. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neurol. 50 (2001) 358-365
38. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 486-510
39. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., and Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63 (2004) 2332-2340
40. Mosconi L., Tsui W.H., De S.S., Li J., Rusinek H., Convit A., Li Y., Boppana M., and de Leon M.J. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64 (2005) 1860-1867
41. Mosconi L., Tsui W.H., Pupi A., De S.S., Drzezga A., Minoshima S., and de Leon M.J. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J. Nucl. Med. 48 (2007) 1129-1134
42. Mosconi L., De S.S., Li J., Tsui W.H., Li Y., Boppana M., Laska E., Rusinek H., and de Leon M.J. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 29 (2008) 676-692
43. Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Reiman E.M., Holthoff V., Kalbe E., Sorbi S., ehl-Schmid J., Perneczky R., Clerici F., Caselli R., Beuthien-Baumann B., Kurz A., Minoshima S., and de Leon M.J. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 49 (2008) 390-398
44. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., Trojanowski J.Q., Toga A.W., and Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1 (2005) 55-66
45. Nestor P.J., Fryer T.D., Smielewski P., and Hodges J.R. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 54 (2003) 343-351
46. Perneczky R., Hartmann J., Grimmer T., Drzezga A., and Kurz A. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J. Geriatr. Psychiatry Neurol. 20 (2007) 84-88
47. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 (2001) 1985-1992
48. Reiman, E.M., Langbaum, J.B.S., in press. Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. In: Jagust, W. J., D'Esposito, M. (Eds.), Imaging and the Aging Brain. Oxford University Press, New York.
49. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., and Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the e{open}4 allele for apolipoprotein E. N. Engl. J. Med. 334 (1996) 752-758
50. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., and Frost J. Declining brain activity in cognitively normal apolipoprotein E e{open}4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3334-3339
51. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., and Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 284-289
52. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., and Hardy J. Correlations between apolipoprotein E e{open}4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8299-8302
53. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., Hoffman J.M., Welsh-Bohmer K.A., Alavi A., Clark C.M., Salmon E., de Leon M.J., Mielke R., Cummings J.L., Kowell A.P., Gambhir S.S., Hoh C.K., and Phelps M.E. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
54. Small G.W., Mazziotta J.C., Collins M.T., Baxter L.R., Phelps M.E., Mandelkern M.A., Kaplan A., La Rue A., Adamson C.F., and Chang L. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273 (1995) 942-947
55. Smith G.S., de Leon M.J., George A.E., Kluger A., Volkow N.D., McRae T., Golomb J., Ferris S.H., Reisberg B., and Ciaravino J. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch. Neurol. 49 (1992) 1142-1150
56. Talairach J., and Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain (1988), Thieme Medical Publishers, New York